US Edition
Half-dose apixaban noninferior for preventing recurrent VTE in cancer patients
Summary by medwirenews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Half-dose apixaban noninferior for preventing recurrent VTE in cancer patients
By Lynda Williams, medwireNews ReportermedwireNews: For patients with active cancer and venous thromboembolism, a reduced dose of apixaban is noninferior to the standard dose for preventing recurrent thromboembolic episodes and significantly reduces the risk of clinically relevant bleeding, report the API-CAT investigators.This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.Read the full st…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
